
Cinchophen
CAS No. 132-60-5
Cinchophen( Cinchopen | Mylofanol | Agotan | Phenophan | Tervalon | NSC2617 )
Catalog No. M11303 CAS No. 132-60-5
Cinchophen is an analgesic drug that is frequently used to treat gout.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
500MG | 37 | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameCinchophen
-
NoteResearch use only, not for human use.
-
Brief DescriptionCinchophen is an analgesic drug that is frequently used to treat gout.
-
DescriptionCinchophen is an analgesic drug that is frequently used to treat gout.(In Vivo):Cinchophen (oral gavage; 25-44 mg/kg; twice daily) combines prednisolone ( 0.125-0.220 mg/kg; twice daily) for 14 days is effective in dogs with osteoarthritis and well tolerated. The combination exhibits significantly improved lameness, weight bearing, joint mobility and stiffness scores and is similar in clinical efficacy to phenylbutazone.The kinetics and efficacy of a cinchophen prednisolone combination preparation (PLT) is tested. Cinchophen administation at a dose rate of 12.5 mg/kg intravenously exhibits a volume of distribution (Vd area) of 0.13 L/kg, shows a clearance rate (Cl) of 0.15 L/h and a half-life (t1/2β) of 7.92 hours. The plasma concentration time curve (AUC0-∞) is 1187.0 μ/ml.h in dogs.Cinchophen administation (oral gavage; 12.5 mg/kg; single dose) exhibits a mean maximum plasma concentration (Cmax) of 77.75 μg/ml and the time of Cmax (tmax) is 2.76 hours. The plasma concentration time curve (AUC0-∞) is almost as large following oral as intravenous administration indicating an oral bioavailability (F) of 87.21%.
-
In Vitro——
-
In VivoCinchophen (oral gavage; 25-44 mg/kg; twice daily) combines prednisolone ( 0.125-0.220 mg/kg; twice daily) for 14 days is effective in dogs with osteoarthritis and well tolerated. The combination exhibits significantly improved lameness, weight bearing, joint mobility and stiffness scores and is similar in clinical efficacy to phenylbutazone.The kinetics and efficacy of a cinchophen prednisolone combination preparation (PLT) is tested. Cinchophen administation at a dose rate of 12.5 mg/kg intravenously exhibits a volume of distribution (Vd area) of 0.13 L/kg, shows a clearance rate (Cl) of 0.15 L/h and a half-life (t1/2β) of 7.92 hours. The plasma concentration time curve (AUC0-∞) is 1187.0 μ/ml.h in dogs.Cinchophen administation (oral gavage; 12.5 mg/kg; single dose) exhibits a mean maximum plasma concentration (Cmax) of 77.75 μg/ml and the time of Cmax (tmax) is 2.76 hours. The plasma concentration time curve (AUC0-∞) is almost as large following oral as intravenous administration indicating an oral bioavailability (F) of 87.21%.
-
SynonymsCinchopen | Mylofanol | Agotan | Phenophan | Tervalon | NSC2617
-
PathwayChromatin/Epigenetic
-
TargetCOX
-
RecptorCOX
-
Research AreaInflammation/Immunology
-
Indication——
Chemical Information
-
CAS Number132-60-5
-
Formula Weight249.26
-
Molecular FormulaC16H11NO2
-
Purity>98% (HPLC)
-
SolubilityEthanol: 5 mg/mL (20.05 mM); DMSO: 50 mg/mL (200.59 mM)
-
SMILESO=C(O)C1=CC(C2=CC=CC=C2)=NC3=CC=CC=C13
-
Chemical Name2-Phenylcinchoninic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Cutrín Prieto C, et al. Med Clin (Barc). 1991 Jun 15; 97(3):104-6.
molnova catalog



related products
-
Astragaloside I
Astragaloside I is a natural product isolated from Astragalus.
-
Hederagenin
Hederagenin is a triterpenoid saponin inhibiting LPS-stimulated expression of iNOS, COX-2, and NF-κB.
-
Sudoxicam
Sudoxicam is a reversible antagonist of COX with anti-inflammatory, anti-edema, and antipyretic properties.